Custom linker-payload design, conjugation, characterization, and translational support to advance ADCs and XDCs from concept to preclinical readiness.
Antibody-drug conjugates require coordinated expertise across antibody biology, synthetic chemistry, conjugation strategy, analytical characterization, pharmacology, DMPK, and early safety evaluation.
ChemPartner provides an integrated ADC/XDC development platform to help biopharma teams design, generate, screen, optimize, and advance conjugated candidates with speed and scientific rigor.
Integrated ADC/XDC Development from Discovery to IND
ChemPartner supports ADC and XDC programs through a connected development workflow spanning antibody optimization, linker-payload design, conjugation, characterization, translational evaluation, and development support.
We offer a connected platform to design, screen, optimize, and advance ADC/XDC candidates toward preclinical readiness.
Why Partner with ChemPartner for ADC Development?
Integrated expertise, proven scale, and modality breadth for ADC/XDC discovery and early development.
Chemistry & Conjugation
Design and build ADC/XDC candidates with integrated linker-payload chemistry, conjugation strategy, and process development support.
Linker-Payload Chemistry
Custom Linker-Payload Design for ADC Optimization
ChemPartner’s chemistry team supports the design and synthesis of custom linker-payload systems, including hydrophilic linkers, charged linkers, branched multi-drug linkers, click chemistry handles, and bioorthogonal linker strategies.
Our linker-payload chemistry capabilities are designed to help optimize ADC potency, stability, hydrophilicity, DAR, payload release, and manufacturability across diverse target and payload strategies.
Bioconjugation and Process Development
Flexible Conjugation Strategies for Conventional and Next-Generation ADCs
With over 15 years of ADC drug conjugation and process development experience, ChemPartner delivers both chemical and enzyme-catalyzed site-specific conjugation across a broad range of formats from random to fully site-specific.
Our capabilities span lysine, cysteine, Thiomab, mTG- and Sortase A-catalyzed, glycan, click chemistry, and multi-drug conjugation approaches.
From early feasibility batches to process development, our team supports conjugation strategies tailored to each program’s biology, payload, DAR target, and developability requirements across conventional ADCs and next-generation XDCs.
High-Throughput ADC Conjugation
Screen More ADC Designs, Faster
ChemPartner’s high-throughput ADC conjugation platform enables the preparation of up to 96 candidates per batch at microgram scale, with consistent DAR performance and high quality throughout.
Designed for rapid ADC screening and optimization, it supports hybridoma-derived antibodies and streamlines early-stage development workflows, reducing both timeline and resource demands.
Characterization & Bioactivity
Characterize ADC/XDC quality, consistency, and function with integrated analytical and in vitro bioactivity platforms.
ADC/XDC Characterization
Analytical Confidence from Conjugation to Candidate Selection
ChemPartner’s characterization platform provides comprehensive physicochemical and functional analysis for ADCs and related conjugates, covering candidate quality, consistency, stability, and biological performance to support data-driven optimization and selection.
Key Capabilities:
DAR analysis: SEC-MS, RPLC-MS, HIC, RPLC, and UV/VIS |
Purity analysis: SEC-HPLC and CE-SDS |
Charge variant analysis: iCIEF and CEX |
Affinity assessment: SPR and BLI |
Structural and stability analysis: By CD, DSC/DSF, and DLS |
Release testing: Free drug, residual solvent, linker residue, endotoxin, bioburden, and peptide map analysis |
In Vitro Bioactivity Characterization
Functional Assays to Connect ADC Design with Biological Activity
ChemPartner supports in vitro ADC functional assays including target binding, internalization, cytotoxicity, bystander killing, ADCC, CDC, and related mechanism-of-action studies.
These assays help confirm whether linker-payload and conjugation design choices translate into functional antitumor activity and candidate differentiation.
Core Assay Capabilities:
FACS-based binding analysis |
Internalization assay |
Cytotoxicity assay |
Bystander killing assay |
ADCC and CDC analysis |
Immunogenic cell death and mechanism-related functional assays |
Plasma Stability Assay
Assess Linker Stability and Payload Release Risk Early
ChemPartner’s plasma stability assays help assess premature linker cleavage and early payload release risk before in vivo studies.
These studies support linker-payload optimization by monitoring ADC stability, DAR change, binding retention, and payload release behavior under relevant plasma conditions.
Assessment Readouts:
Payload release profiling by LC-MS/MS |
DAR value monitoring |
ELISA-based binding analysis |
Aggregation assessment |
Stability comparison across timepoints and conditions |
In Vivo & DMPK/Tox
Advance promising ADC candidates with in vivo pharmacology, bioanalysis, DMPK evaluation, and exploratory toxicology support.
In Vivo Pharmacology and Efficacy
Translational Models for ADC Efficacy and Combination Strategy
ChemPartner provides in vivo efficacy support across CDX, PDX, syngeneic, orthotopic, metastatic, and disseminated tumor models. Our in vivo pharmacology platform helps evaluate antitumor activity, dose response, combination potential, tolerability, and PK/PD relationships to support preclinical decision-making.
Model capabilities:
- 320+ human tumor cell line xenograft models
- Subcutaneous, orthotopic, metastatic, and disseminated models
- 500+ PDX models
- 60+ PDX-derived primary tumor models
- 50+ syngeneic models
- MTD studies in tumor-bearing and non-tumor-bearing mice
- PK, PD, and PK/PD correlation studies
DMPK and Exploratory Toxicology
De-Risk ADC Candidates Before IND-Enabling Development
ChemPartner provides integrated bioanalytical and DMPK support to characterize total antibody, conjugated antibody, free payload, stability, DAR changes, and exposure-response relationships.
These studies help assess systemic exposure, payload release, and early translational risk before IND-enabling development.
Key Capabilities:
Total antibody, conjugated antibody, and free payload analysis |
Mouse, rat, and NHP PK studies |
PK/PD model evaluation |
Payload release and metabolism studies |
In vitro ADME assessment |
Exploratory toxicology studies |
Target-mediated clearance evaluation in cynomolgus NHP |
Target-Mediated Clearance in Cynomolgus NHP
ADC Bioanalysis
Quantitative and qualitative bioanalysis for complex ADC programs
ChemPartner provides ADC bioanalysis services to measure the critical components that define ADC exposure, stability, and pharmacological behavior.
This includes free payload, conjugated antibody, total antibody, DAR value changes, and payload-related metabolites.
CMC/GMP Bridge
Connect discovery-stage ADC work with development, scale-up, formulation, and GMP-ready support through an integrated CRO/CDMO model.
CMC and GMP Bridge for ADC Programs
From Discovery CRO to Development and Manufacturing Partner
For programs advancing beyond discovery, ChemPartner provides end-to-end CMC and manufacturing support to reduce handoff risk as candidates move toward IND-ready stages.
- CMC and manufacturing support
- Developability assessment
- Cell line development, banking, and stability
- Cell culture and purification process development
- Formulation and lyophilization process development
- Analytical development and validation
- Process transfer and scale-up
- Pilot-scale GMP production
- 500L and 2000L GMP manufacturing
- Stability studies and comparability studies
- IND documentation and registration support
Advance Your ADC Program with an Integrated CRO/CDMO Partner
Whether you are validating an early ADC concept, optimizing linker-payload design, comparing conjugation strategies, screening candidates, or preparing for translational development, ChemPartner provides the integrated expertise to support your next milestone.
